Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

Recruiting now

Conditions studied: Relapsed/Refractory Follicular Lymphoma

In brief

Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).

Key facts

Study ID

NCT07278921

Run by

Andrés José Maria Ferreri

People needed

25

Starts

2025-12-01

Expected to finish

2026-12-31

Last updated by the study team

2026-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (>18 years) with follicular non-Hodgkin's lymphoma, undergoing at least two lines of therapy, treated with mosunetuzumab under a compassionate use program.
• Patients who have signed informed consent for treatment.

You may not qualify if…

• Age <18 years
• Patients with other types of cancer/lymphoma
• Patients not eligible for the Mosunetuzumab compassionate use program

Where it is running

• IRCCS Ospedale San Raffaele — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.